Portal de investigación
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Stahl, M
- DeVeaux, M
- Itzykson, R
- Ritchie, EK
- Sekeres, MA
- Barnard, J
- Podoltsev, NA
- Brunner, A
- Komrokji, RS
- Bhatt, VR
- Al-Kali, A
- Cluzeau, T
- Santini, V
- Roboz, GJ
- Fenaux, P
- Litzow, M
- Fathi, AT
- Perreault, S
- Kim, TK
- Prebet, T
- Vey, N
- Verma, V
- Germing, U
- Bergua, J
- Serrano, J
- Gore, SD
- Zeidan, AM
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 1042-8194, 1029-2403
- Tipo:
- Letter
- Páginas:
- 246-249
- PubMed:
- 29963936
- Factor de Impacto:
- 0,886 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
LEUKEMIA & LYMPHOMA TAYLOR & FRANCIS LTD
Documentos
- No hay documentos
Filiaciones
Campos de Estudio
Cita
Stahl M,DeVeaux M,Montesinos P,Itzykson R,Ritchie EK,Sekeres MA,Barnard J,Podoltsev NA,Brunner A,Komrokji RS,Bhatt VR,Al A,Cluzeau T,Santini V,Roboz GJ,Fenaux P,Litzow M,Fathi AT,Perreault S,Kim TK,Prebet T,Vey N,Verma V,Germing U,Bergua J,Serrano J,Gore SD,Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leuk. Lymphoma. 2019. 60(1):p. 246-249. IF:2,969. (2).